Pts with advanced NSCLC;PM8002 mono; Treatment-naïve no-sq-NSCLC with EGFR/ALK wild-type and PD-L1+, N=17; EGRF-TKI treated no-sq-NSCLC, N=36; IO and PBC treated NSCLC with EGFR/ALK wild-type, N=8;. This evidence concerns the gene ALK and non-small cell lung carcinoma.